347 related articles for article (PubMed ID: 14632309)
1. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
Schaefer C
Birth Defects Res A Clin Mol Teratol; 2003 Aug; 67(8):591-4. PubMed ID: 14632309
[TBL] [Abstract][Full Text] [Related]
2. [Teratogenic effects of ACE-inhibitors and angiotensin II receptor antagonists].
Sørensen AM; Christensen S; Jonassen TE; Andersen D; Petersen JS
Ugeskr Laeger; 1998 Mar; 160(10):1460-4. PubMed ID: 9520613
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors.
Cooper WO
J Cardiovasc Nurs; 2008; 23(1):20-4. PubMed ID: 18158502
[TBL] [Abstract][Full Text] [Related]
4. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Quan A
Early Hum Dev; 2006 Jan; 82(1):23-8. PubMed ID: 16427219
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonist treatment during pregnancy.
Alwan S; Polifka JE; Friedman JM
Birth Defects Res A Clin Mol Teratol; 2005 Feb; 73(2):123-30. PubMed ID: 15669052
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors.
Piper JM; Ray WA; Rosa FW
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):429-32. PubMed ID: 1495700
[TBL] [Abstract][Full Text] [Related]
7. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy.
Hanssens M; Keirse MJ; Vankelecom F; Van Assche FA
Obstet Gynecol; 1991 Jul; 78(1):128-35. PubMed ID: 2047053
[TBL] [Abstract][Full Text] [Related]
8. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
Walfisch A; Al-maawali A; Moretti ME; Nickel C; Koren G
J Obstet Gynaecol; 2011 Aug; 31(6):465-72. PubMed ID: 21823839
[TBL] [Abstract][Full Text] [Related]
9. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment.
Tabacova S; Little R; Tsong Y; Vega A; Kimmel CA
Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):633-46. PubMed ID: 14762979
[TBL] [Abstract][Full Text] [Related]
10. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D
Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
[TBL] [Abstract][Full Text] [Related]
11. Major congenital malformations after first-trimester exposure to ACE inhibitors.
Cooper WO; Hernandez-Diaz S; Arbogast PG; Dudley JA; Dyer S; Gideon PS; Hall K; Ray WA
N Engl J Med; 2006 Jun; 354(23):2443-51. PubMed ID: 16760444
[TBL] [Abstract][Full Text] [Related]
12. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
de Leeuw PW
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1605-7. PubMed ID: 16901062
[TBL] [Abstract][Full Text] [Related]
13. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.
Schaefer C; Meister R; Weber-Schoendorfer C
Arch Gynecol Obstet; 2010 Feb; 281(2):221-7. PubMed ID: 19444462
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services.
Garbis H; Elefant E; Diav-Citrin O; Mastroiacovo P; Schaefer C; Vial T; Clementi M; Valti E; McElhatton P; Smorlesi C; Rodriguez EP; Robert-Gnansia E; Merlob P; Peiker G; Pexieder T; Schueler L; Ritvanen A; Mathieu-Nolf M
Reprod Toxicol; 2005; 19(4):453-8. PubMed ID: 15749258
[TBL] [Abstract][Full Text] [Related]
16. Neonatal anuria with maternal angiotensin-converting enzyme inhibition.
Rosa FW; Bosco LA; Graham CF; Milstien JB; Dreis M; Creamer J
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):371-4. PubMed ID: 2761913
[TBL] [Abstract][Full Text] [Related]
17. [Angioedema induced by ACE inhibitors and angiotensin II-receptor antagonists: analysis of 98 cases].
Schuster C; Reinhart WH; Hartmann K; Kuhn M
Schweiz Med Wochenschr; 1999 Mar; 129(9):362-9. PubMed ID: 10198947
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
Diav-Citrin O; Shechtman S; Halberstadt Y; Finkel-Pekarsky V; Wajnberg R; Arnon J; Di Gianantonio E; Clementi M; Ornoy A
Reprod Toxicol; 2011 May; 31(4):540-5. PubMed ID: 21338666
[TBL] [Abstract][Full Text] [Related]
19. Teratogenicity with angiotensin II receptor antagonists in pregnancy.
Boix E; Zapater P; Picó A; Moreno O
J Endocrinol Invest; 2005 Dec; 28(11):1029-31. PubMed ID: 16483184
[TBL] [Abstract][Full Text] [Related]
20. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study.
Schaefer C; Hannemann D; Meister R; Eléfant E; Paulus W; Vial T; Reuvers M; Robert-Gnansia E; Arnon J; De Santis M; Clementi M; Rodriguez-Pinilla E; Dolivo A; Merlob P
Thromb Haemost; 2006 Jun; 95(6):949-57. PubMed ID: 16732373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
